Clinical Trial Update: A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of RO5212054 (PLX3603) in patients with BRAF V600-mutated advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Braf V600-mutated Solid Tumors

Drugs mentioned

• RO5212054 (PLX3603) (RO5212054)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neoplasms | Phase 1 | Status: COMPLETED